Dr Reddy’s semaglutide Canada update: 2026 caution

What changed for Dr Reddy’s on April 24

Dr Reddy’s Laboratories came under pressure in Friday’s trade after the company clarified that it is still awaiting approval from Health Canada for its semaglutide injection. The stock had rallied sharply a day earlier on market chatter about a possible regulatory nod in Canada. As brokerages revisited the risk-reward after the surge, the tone turned more cautious. The move highlighted how quickly sentiment can swing on incremental regulatory updates in high-demand therapies.

As per the latest NSE data cited in the report, Dr Reddy’s shares were trading at ₹1,316, down ₹15 or 1.13%. Another market update in the same set of reports put the stock at ₹1,309.50 at 1032 IST, down 1.6% on the NSE, after opening nearly 3% lower. Trading activity also remained elevated, with over 2 million shares reported traded by 1032 IST.

The exchange filing: approval is still awaited

In its stock exchange filing, Dr Reddy’s responded to a CNBC-TV18 report that said the company was still awaiting a key near-term trigger. The company stated the headline was correct because it has not yet received approval, described as a “Notice of Compliance”, for its semaglutide injection from Health Canada. This clarification was the central factor behind the cooling of expectations built into Thursday’s rally.

The filing also contained an important process update. Dr Reddy’s said it received Drug Identification Numbers (DINs) for semaglutide injection from Health Canada on April 22, 2026. The company added that it continues to engage with the regulator and remains committed to bringing the product to the Canadian market upon approval. The wording underscored that the regulatory process is progressing, but the key commercial green light is still pending.

Why the stock moved: a rally on “unconfirmed” approval chatter

The sharp stock move began on April 23, 2026, when the shares jumped as reports pointed to a possible approval for a generic version of semaglutide in Canada. One report described the move as a 9.4% rise, the sharpest single-session gain since September 2017. The broader pharma pack also firmed up alongside Dr Reddy’s, as investors bought into the GLP-1 opportunity narrative and value-chain positioning.

But the next day’s reaction showed that the market had moved ahead of confirmed regulatory outcomes. Citi argued that the company’s recent 9% rally on unconfirmed news likely overstated the upside. The company’s own filing later aligned with the “awaiting approval” framing, reinforcing the broker view that the price action had discounted an event that had not yet happened.

Citi’s view: competitive pressure caps the opportunity

Citi maintained a ‘Sell’ rating on Dr Reddy’s with a target price of ₹1,070 per share. The brokerage said the stock’s rally overstated the potential, especially in a market where competition is expected to build quickly. Citi also quantified the likely economics in Canada as other players line up for the same opportunity.

According to Citi’s estimates cited in the report, Dr Reddy’s could earn USD 80 million to USD 100 million from semaglutide sales in a three-player Canadian market that includes Dr Reddy’s, Sandoz Group, and Apotex. In FY28, Citi estimates semaglutide sales for Dr Reddy’s at around USD 50 million in a six-player market. The brokerage also noted that Teva Pharmaceutical Industries, Sun Pharma, and Aspen Pharmacare Holdings have filed for approvals for generic semaglutide drugs.

Goldman Sachs downgrade: “short-lived” upside risk

Goldman Sachs downgraded Dr Reddy’s to ‘Sell’ from Neutral and set a target price of ₹1,075 per share. The brokerage said that even if approval comes through, the Ozempic opportunity in Canada may be short-lived. The reasoning, as presented in the report, aligns with the broader concern that pricing and market share can compress rapidly once multiple generics enter.

Together, Citi and Goldman’s calls shifted the discussion from “approval as a catalyst” to “approval economics under competition”. That distinction mattered after a one-day move of this magnitude, especially when the company’s filing confirmed that the key Notice of Compliance was still awaited.

Market data points investors tracked during the move

Price and volume commentary in the reports indicated heavy participation across the two sessions. Over 16 million shares reportedly changed hands in the full session on Thursday, following the semaglutide-approval chatter. On Friday, the stock opened sharply lower but came off the day’s lows after the company’s clarification.

Separately, the broader set of reports also referenced another negative development tied to semaglutide. Dr Reddy’s semaglutide generic, Embeltah, was rejected by Brazil’s regulator ANVISA, and one report linked that to negative sentiment on the stock during Indian trading, including an intraday low of ₹1,195.40 and a later reading of ₹1,217.80 at 1232 IST.

Financial context cited alongside the headlines

The reports also referenced Dr Reddy’s revenue performance in the same news flow. Revenue rose 2% to ₹46,402 crore (INR 464.02 billion), slightly missing the Street view of ₹46,579 crore (INR 465.79 billion). While the semaglutide narrative dominated short-term trading, these figures provided context on the company’s broader operating baseline.

The coverage also noted that investors are watching multiple regulatory events beyond Canada. Another report cited that Dr Reddy’s received marketing authorisation for its semaglutide injection in India from the DCGI, and that necessary local manufacturing licences have been secured.

Key facts table

Why this matters for investors

The episode showed how GLP-1 related headlines can move large-cap pharma stocks even before final regulatory outcomes. Dr Reddy’s confirmation that it is still awaiting Health Canada’s Notice of Compliance brought the focus back to process milestones rather than market speculation. Broker caution centred on competitive intensity, which can reduce the duration and scale of any first-mover benefit.

Near term, investors are likely to track additional updates from Health Canada, including whether the Notice of Compliance arrives and how quickly competing filers progress. Broker models in the reports already incorporate a multi-player market structure, suggesting that approval alone may not be enough to support the re-rating implied by the one-day rally.

Conclusion

Dr Reddy’s shares fell after the company clarified that semaglutide approval in Canada is still pending, even as it received DINs from Health Canada on April 22, 2026. Citi and Goldman Sachs maintained cautious views, highlighting competition and the risk that the opportunity could be limited in duration. The next decisive trigger, as described in the company’s filing, remains the Notice of Compliance from Health Canada.